Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Leonard Marks MD

Leonard S. Marks MD

deKernion Endowed Chair in Urology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California

Dr. Marks is Professor of Urology at the David Geffen School of Medicine at UCLA. He was graduated from the University of Texas, where he received the M.D. with AOA honors and Masters of Arts (Physiology) degrees in 1969. He served an internship and surgical residency at UCLA/Harbor General Hospital. For 2 years after that, he served on active duty as Lt. Cdr. in the U.S. Public Health Service. He was named a Post-Doctoral Research Scholar at UCLA School of Medicine in 1973-4. He completed his urology residency at UCLA and was Lecturer in Urology there in 1978, following which he entered private practice in Los Angeles.   He re-joined the UCLA faculty full-time in 2009.

While in practice, Dr. Marks founded a non-profit research organization, Urological Sciences Research Foundation, a 501c3 corporation, to further his academic interests. He became an original AFUD scholar in 1992 for work relating serum PSA levels to prostate histology. He received a Prostate Cancer Foundation (PCF) research award in 2000 for cross-cultural studies of prostate cancer. An early advocate of multimedia in urology, he served as Website Editor of Urology (The Gold Journal) from 1998-2010.  For his work in the scientific evaluation of alternative medicines,  he was appointed to committees of the American Urological Association, the National Institutes of Health (NCCCAM and NIDDK), and the National Academy of Sciences. 

He has for the past 3 years been Principle Investigator of an R01 Award from the National Cancer Institute, devoted to targeted prostate biopsy. He has authored more than 120 scientific publications.

Recent Contributions to PracticeUpdate:

  1. Risk of Prostate Cancer Progression in Active Surveillance Patients With Bilateral Disease
  2. Systematic Biopsy of the Prostate Can Be Omitted in Men With PI-RADS™ 5 and PSA Density >15
  3. Transperineal Prostate Biopsy Improves the Detection of Clinically Significant Prostate Cancer Among Men on Active Surveillance
  4. Perilesional Biopsies Increase Detection of Significant Prostate Cancer in Men With PI-RADS 4/5 Lesions
  5. Intraprostatic Cancer Recurrence Following Radical Radiotherapy on Transperineal Template Mapping Biopsy: Implications for Focal Ablative Salvage Therapy
  6. Active Surveillance of Grade Group 1 Prostate Cancer
  7. 3-Year Active Surveillance Outcomes in a Contemporary Community Urology Cohort in the US
  8. MRI Biopsy Techniques for the Diagnosis of Prostate Cancer in Patients With Prior Negative Biopsies
  9. Clinical Prediction Tool to Determine the Need for Concurrent Systematic Sampling at the Time of MRI-Guided Biopsy
  10. Men With Negative Prostate MRI May Not Need Standard Biopsy

Recently Updated